Oleg A. Gladkov
42, Blukhera Str, 454087
Chelyabinsk, CHE, Russian Federation
Chelyabinsk, CHE, Russian Federation
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLC.
Journal: Clinical lung cancer
Published: October 30, 2025
Corrigendum to "Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial" [Eur J Cancer. 227 (2025) 115674].
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 31, 2025
Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 15, 2025
Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 23, 2024
Cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non-small cell lung cancer with programmed cell death-ligand 1 ≥50.
Journal: Cancer
Published: August 16, 2024
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 05, 2023
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Journal: Lancet (London, England)
Published: September 21, 2020
Management of Muscle Invasive Bladder Cancer with Bladder Preservation in Russia: a Survey-Based Analysis of Current Practice and the Impact of an Educational Workshop on Clinical Expertise.
Journal: Journal of cancer education : the official journal of the American Association for Cancer Education
Published: March 05, 2020
Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: December 11, 2015
A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer.
Journal: Molecular cancer therapeutics
Published: November 11, 2015
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: November 09, 2015
A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.
Journal: International journal of cancer
Published: September 11, 2015
Last Updated: 09/26/2026